

1 **Dynamics of T cell responses to COVID-19 vaccines and breakthrough infection in**
2 **people living with HIV receiving antiretroviral therapy**

3
4
5 Sneha Datwani^{1*}, Rebecca Kalikawe^{1*}, Rachel Waterworth^{1,3}, Francis M. Mwimanzi¹,
6 Richard Liang², Yurou Sang¹, Hope R. Lapointe², Peter K. Cheung^{1,2}, F. Harrison
7 Omondi^{1,2}, Maggie C. Duncan^{1,2}, Evan Barad^{1,2}, Sarah Speckmaier², Nadia Moran-
8 Garcia², Mari L. DeMarco^{4,5}, Malcolm Hedgcock⁶, Cecilia T. Costiniuk⁷, Mark Hull^{2,8},
9 Marianne Harris^{2,9}, Marc G. Romney^{4,5}, Julio S.G. Montaner^{2,8}, Zabrina L. Brumme^{1,2#},
10 Mark A. Brockman^{1,2,3#}

11
12 ¹ Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada;

13 ² British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada

14 ³ Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby,
15 Canada;

16 ⁴ Department of Pathology and Laboratory Medicine, Providence Health Care,
17 Vancouver, Canada;

18 ⁵ Department of Pathology and Laboratory Medicine, University of British Columbia,
19 Vancouver, Canada

20 ⁶ Spectrum Health, Vancouver, Canada

21 ⁷ Division of Infectious Diseases and Chronic Viral Illness Service, McGill University
22 Health Centre and Research Institute of the McGill University Health Centre, Montreal,
23 Quebec, Canada

24 ⁸ Department of Medicine, University of British Columbia, Vancouver, Canada;

25 ⁹ Department of Family Practice, Faculty of Medicine, University of British Columbia,
26 Canada

27
28 *equal contribution

29 #Corresponding authors: MAB, mark_brockman@sfu.ca; ZLB, zbrumme@sfu.ca

30
31 Abstract: 349 words

32 Text: 4,102 words

33 Inserts: 5 (1 Table, 4 Figures)

34 Supplemental files: 5 (2 Supplemental Figures, 3 Supplemental Tables)

35
36 **Keywords:** Covid-19, SARS-CoV-2, coronavirus, vaccine, T cells, HIV, antiretroviral
37 therapy

39 **ABSTRACT** (349 words)

40 **Introduction:** People living with HIV (PLWH) can exhibit impaired immune responses
41 to vaccines. Accumulating evidence indicates that PLWH, particularly those receiving
42 antiretroviral therapy, mount strong antibody responses to COVID-19 vaccination, but
43 fewer studies have examined cellular immune responses to vaccination. We measured
44 SARS-CoV-2 spike-specific CD4⁺ and CD8⁺ T cell responses generated by two and
45 three doses of COVID-19 vaccine in PLWH receiving antiretroviral therapy, compared to
46 control participants without HIV. We also quantified T cell responses after post-vaccine
47 breakthrough infection, and receipt of fourth vaccine doses, in a subset of PLWH.

48

49 **Methods:** We quantified CD4⁺ and CD8⁺ T cells reactive to overlapping peptides
50 spanning the ancestral SARS-CoV-2 spike protein in 50 PLWH and 87 controls without
51 HIV, using an activation induced marker (AIM) assay. All participants remained SARS-
52 CoV-2 naïve until at least one month after their third vaccine dose. SARS-CoV-2
53 infection was determined by seroconversion to nucleocapsid (N) antigen, which occurred
54 in 21 PLWH and 38 controls post-third dose. Multivariable regression analyses were used
55 to investigate relationships between sociodemographic, health and vaccine-related
56 variables and vaccine-induced T cell responses, as well as breakthrough infection risk.

57

58 **Results:** A third vaccine dose boosted spike-specific CD4⁺ and CD8⁺ T cell frequencies
59 significantly above those measured after the second dose (all $p < 0.0001$). Median T cell
60 frequencies did not differ between PLWH and controls after the second dose ($p > 0.1$), but
61 CD8⁺ T cell responses were modestly lower in PLWH after the third dose ($p = 0.02$), an

62 observation that remained significant after adjustment for sociodemographic, health and
63 vaccine-related variables ($p=0.045$). In PLWH who experienced breakthrough infection,
64 median T cell frequencies increased even higher than those observed after three vaccine
65 doses ($p<0.03$), and CD8+ T cell responses in this group remained higher even after a
66 fourth vaccine dose ($p=0.03$). In multivariable analysis, the only factor associated with
67 increased breakthrough infection risk was younger age, consistent with the rapid
68 increases in SARS-CoV-2 seropositivity among younger adults in Canada after the initial
69 appearance of the Omicron variant.

70

71 **Conclusion:** PLWH receiving antiretroviral therapy mount strong T cell responses to
72 COVID-19 vaccines that can be enhanced by booster doses or breakthrough infection.

73 INTRODUCTION

74 Prior to the widespread availability of COVID-19 vaccines, there was evidence
75 that people living with HIV (PLWH) were at increased risk of severe COVID-19
76 outcomes [1-5], making vaccination particularly important in this group. Since then, a
77 growing body of evidence indicates that COVID-19 vaccines have been highly effective
78 at preventing severe disease associated with SARS-CoV-2 infection, including in PLWH
79 [6, 7]. Studies analyzing vaccine-induced immune responses, including from our group,
80 also confirm that PLWH, in particular those who are receiving suppressive antiretroviral
81 therapy, mount robust humoral (antibody) response to COVID-19 immunization [8-16].
82 But comparably fewer studies have investigated the cellular immune response to COVID-
83 19 vaccines in PLWH, which includes CD4+ helper T cells that play a central role in
84 generating antigen-specific B cells and antibodies and CD8+ cytotoxic T cells that
85 recognize and eliminate virus-infected cells [17-20]. Indeed, while COVID-19 vaccines
86 typically induce strong T cell responses [21, 22], the frequency of spike-specific CD4+ T
87 cells following COVID-19 vaccination may be lower in PLWH, in particularly among
88 those with low CD4+ T cell counts [9, 23]. A better understanding of T cell responses
89 elicited by COVID-19 vaccines, as well as breakthrough SARS-CoV-2 infections, will
90 inform ongoing efforts to enhance protective immunity in PLWH.

91 Towards this goal, we investigated the dynamics of spike-specific CD4+ and
92 CD8+ T cell responses elicited after two and three doses of COVID-19 vaccine in a
93 cohort of 50 adult PLWH receiving antiretroviral therapy, and 87 controls without HIV.
94 All participants remained naïve to SARS-CoV-2 until at least one month after their third
95 dose. We additionally investigated spike-specific CD4+ and CD8+ T cell responses in a

96 subset of 21 PLWH who experienced their first SARS-CoV-2 breakthrough infection
97 between one and six months after their third vaccine dose. Overall, our results revealed
98 that spike-specific CD4+ and CD8+ T cell frequencies were boosted with each vaccine
99 dose, and that these responses were broadly comparable between PLWH and controls,
100 with the exception of CD8+ T cell responses after the third dose, which were moderately
101 lower in PLWH compared to controls. Breakthrough infection further boosted median
102 spike-specific T cell frequencies, and CD8+ T cell responses remained higher in these
103 individuals even after a fourth vaccine dose.

104

105 **METHODS**

106 *Participants.* Our cohort of COVID-19 vaccine recipients, based in British Columbia
107 (BC) Canada, has been described previously [10, 13, 24]. Of the 99 PLWH and 152
108 controls (without HIV) originally enrolled in the study, 62 (PLWH) and 117 (controls)
109 remained naïve for SARS-CoV-2 infection until at least one month after their third
110 COVID-19 vaccine dose. Of these, we examined a subset of 50 PLWH and 87 controls,
111 selected largely based on sample availability (**Table 1**).

112

113 *Ethics approval.* Written informed consent was obtained from all participants. This study
114 was approved by the University of British Columbia/Providence Health Care and Simon
115 Fraser University Research Ethics Boards.

116

117 *SARS-CoV-2 seroconversion.* SARS-CoV-2 infection was identified based on the
118 development of serum antibodies against the viral Nucleocapsid (N) protein using the

119 Elecsys Anti-SARS-CoV-2 assay (Roche Diagnostics), combined with diagnostic (PCR-
120 and/or rapid-antigen-test) information where available.

121

122 ***T cell activation induced marker assays.*** Cryopreserved peripheral blood mononuclear
123 cells (PBMC) were thawed and diluted in TexMACS media (Miltenyi Biotec, Cat#130-
124 097-196). PBMC were stimulated at 1×10^6 cells per well for 24 hours with peptide pools
125 spanning the SARS-CoV-2 ancestral spike protein (15-mers, overlapping by 11 amino
126 acids) (Miltenyi Biotec, Cat#130-127-953) in duplicate in a 96-well U-bottom plate.
127 PBMC were incubated with media only (no peptide) as a negative control or 2 $\mu\text{g}/\text{ml}$
128 CytoStim reagent (Miltenyi Biotec, Cat#130-092-172) as a positive control. Following
129 stimulation, cells were labeled with CD8-APC/Cyanine7 (Biolegend, Cat#301016), CD4-
130 FITC (Biolegend, Cat#300538), CD137-APC (Biolegend, Cat#309810), CD69-PE (BD,
131 Cat#555531), OX40-PE-Cy7 (Biolegend, Cat#350012), CD3-PerCP/Cyanine5.5
132 (Biolegend, Cat#317336) CD14-V500 (BD, Cat#561391), CD19-V500 (BD,
133 Cat#561121) and 7-AAD Viability Staining Solution (Biolegend, Cat#420404). Data
134 were acquired on a Beckman Coulter Cytotflex S flow cytometer, with a minimum of
135 10,000 CD3+ T cells assayed per participant. After identifying CD3+CD4+ and
136 CD3+CD8+ T cell subsets, the percentage of stimulated cells was determined based on
137 upregulation of two activation markers, using CD137 and OX40 for CD4+ T cells, and
138 CD137 and CD69 for CD8+ T cells (see gating strategy in **Figure S1**). Data were
139 analyzed in FlowJo version 10.8.1.

140

141 ***SARS-CoV-2 neutralization.*** We previously reported the ability of participant plasma to
142 neutralize ancestral SARS-CoV-2 (isolate USA-WA1/2020; BEI Resources, Cat #NR-
143 52281), based on the results of a live-virus assay [24].

144

145 ***Statistical analyses.*** Continuous variables were compared using the Mann-Whitney U-
146 test (for unpaired data) or Wilcoxon test (for paired measures). Relationships between
147 continuous variables were assessed using Spearman's correlation. Zero-inflated beta
148 regressions were used to investigate the relationship between sociodemographic factors
149 and vaccine-induced T cell responses using a confounder model that adjusted for
150 variables that could influence these responses, or that differed in prevalence between
151 groups. These regressions model the response variable as a beta-distributed random
152 variable whose mean is given by a linear combination of the predictor variables (after a
153 logit transformation). Beta distributions are bounded below and above by 0 and 100%,
154 making this a standard choice of regression for frequency data. Because a beta
155 distribution does not admit values of 0 (or 100), we used a zero-inflated beta distribution,
156 which allows for zeros in the data, to accommodate the minority of non-responders (*i.e.* 0
157 values) in our data. For analyses performed after two-dose vaccination, included
158 variables were: HIV status (non-PLWH as reference), age (per year), sex at birth (female
159 as reference), ethnicity (non-white as reference), chronic conditions (per condition),
160 ChAdOx1-containing initial vaccine regimen (mRNA only vaccination as reference) and
161 the interval between first and second doses (per day). Analyses performed after three-
162 dose vaccination also included the third COVID-19 mRNA dose brand (BNT162b2 as
163 reference), the interval between second and third doses (per day), and the % spike-

164 specific T cells after two doses (per percent increase). Multivariable logistic regression
165 was used to explore the relationship between these same variables and the risk of SARS-
166 CoV-2 breakthrough infection between one and six months after the third vaccine dose.
167 All tests were two-tailed, with $p < 0.05$ considered statistically significant. Analyses were
168 conducted using Prism v9.2.0 (GraphPad) and in R.

169

170 **RESULTS**

171 *Participant characteristics*

172 Characteristics of the 50 PLWH and 87 controls without HIV are shown in **Table**

173 **1.** All participants remained COVID-19 naïve until at least one month after their third
174 vaccine dose, as confirmed by repeated negative serology for SARS-CoV-2 anti-N
175 antibodies, and lack of reporting of any SARS-CoV-2 positive test result (either by PCR
176 or rapid antigen test), up to this time point. PLWH and controls were a median age of 58
177 (interquartile range [IQR] 42-65) and 50 (IQR 35-72) years old, respectively, and
178 predominantly of white ethnicity (72% of PLWH and 57% of controls). Most PLWH
179 were male (88%, reflecting the overall population of PLWH in BC), while most controls
180 were female (67%, broadly reflecting the overall demographics of health care workers in
181 the region, from which the controls were predominantly recruited). Both groups reported
182 few chronic health conditions (excluding HIV infection; median 1 [IQR 0-1] in PLWH,
183 versus median 0 [IQR 0-1] in controls). All PLWH were receiving combination
184 antiretroviral therapy, with a median HIV plasma viral load of < 50 copies/mL (IQR < 50 -
185 < 50 copies/mL) at study entry. The median CD4⁺ T cell count at study entry among

186 PLWH was 695 (IQR 468-983) cells per mm³, while median nadir CD4+ T cell count
187 was 250 (IQR 140-490) cells per mm³.

188 Most participants (84% of PLWH and 97% of controls) initially received two
189 doses of mRNA vaccine, either BNT162b2 or mRNA-1273; the remainder received at
190 least one ChAdOx1 dose in their initial series. In PLWH, second vaccine doses were
191 administered a median of 59 days after the first, compared to an median interval of 89
192 days in controls (p<0.0001). This is because Canada delayed second doses well beyond
193 the manufacturers' recommended 21-28 day interval, due to initially limited availability
194 of vaccine supplies in the country [25]. As a result, individuals who received their first
195 doses early in the vaccination campaign, including most health care workers, generally
196 waited the longest to receive their second doses. Retrospectively, it was determined that
197 delaying second doses did not reduce vaccine efficacy, and in some cases may have
198 enhanced protection [26] and reduced the risk of myocarditis [27], prompting the World
199 Health Organization to recommend a 2-month (~60-day) interval between first and
200 second doses [28]. As a result, our multivariable analyses adjust for between-dose
201 intervals and other sociodemographic and clinical attributes listed in **Table 1**. Third
202 vaccine doses were predominantly mRNA-1273 (66% of PLWH and 61% of controls)
203 and were administered a median of 182 to 197 days (approximately 6 to 6.5 months) after
204 the second dose. Third mRNA-1273 dose amounts also differed by age and health
205 history: according to vaccine guidelines in British Columbia, adults 65 years of age and
206 older, as well as PLWH with a history of immunodeficiency, were eligible for a 100 mcg
207 dose whereas all others were eligible for a 50 mcg booster dose (all BNT162b2 doses
208 were 30 mcg). A total of 21 (42%) of PLWH and 38 (44%) of controls experienced their

209 first SARS-CoV-2 infection between one and six months after the third vaccine dose, as
210 determined by seroconversion to the SARS-CoV-2 N protein and/or self-reported positive
211 SARS-CoV-2 test results where available. Though viral genotyping was not performed
212 for these “breakthrough” infections, these were likely Omicron BA.1 or BA.2 based on
213 local molecular epidemiology trends at the time [29].

214

215 *T cell responses following two and three COVID-19 vaccine doses*

216 Prior to vaccination, the percentage of spike-specific CD4+ and CD8+ T cells,
217 measured in a subset of 10 PLWH and 15 controls, was negligible as expected (**Figures**
218 **1A, 1B**). Following two vaccine doses, the percentage of spike-specific CD4+ T cells
219 increased significantly from pre-vaccine levels (paired measures $p \leq 0.004$ for both PLWH
220 and controls), reaching a median 0.25% (IQR 0.07-0.50) in PLWH and a median 0.32%
221 (IQR 0.15-0.55) in controls, a difference that was not statistically significant between
222 groups ($p=0.11$; **Figure 1A**). CD8+ T cell responses also increased significantly from
223 pre-vaccine levels following two vaccine doses (paired measures $p \leq 0.002$ in both
224 groups), reaching a median 0.39% (IQR 0.22-0.53) in PLWH and a median 0.31% (IQR
225 0.14-0.61) in controls, a difference that was not statistically significant between groups
226 ($p=0.39$; **Figure 1B**). The lack of statistically significant differences in vaccine-induced T
227 cell responses between PLWH and controls remained after controlling for socio-
228 demographic, health and vaccine-related variables ($p=0.08$ for CD4+ T cell responses;
229 $p=0.99$ for CD8+ T cell responses; **Tables S1 and S2**). Of note, these multivariable
230 analyses did not identify any variables that were significantly associated with spike-
231 specific CD4+ T cell responses after two vaccine doses (**Table S1**), though having

232 received at least one ChAdOx1 dose as part of the initial vaccine series was weakly
233 associated with higher spike-specific CD8+ T cell responses after the second vaccine
234 dose (p=0.049; **Table S2**).

235 A third vaccine dose further boosted the percentage of spike-specific CD4+ T
236 cells beyond the levels observed after two doses (paired measures p<0.0001 for both
237 PLWH and controls; **Figure 1A**). After the third dose, spike-specific CD4+ T cell
238 frequencies reached a median 0.67% (IQR 0.50-0.86) in PLWH compared to a median
239 0.71% (IQR 0.40-0.98) in controls (p=0.52; **Figure 1A**), where this lack of significant
240 difference between groups remained after controlling for sociodemographic, health and
241 vaccine-related variables (p=0.58; **Table S1**). Similarly, a third vaccine dose further
242 boosted the percentage of spike-specific CD8+ T cells (paired measures p<0.0001 for
243 both groups; **Figure 1B**). Somewhat in contrast to the other immune measures however,
244 the median CD8+ T cell response in PLWH (0.61%; IQR 0.43-0.79) was lower compared
245 to that of controls (0.78%; IQR 0.43-1.1) after the third vaccine dose (p=0.02; **Figure**
246 **1B**). This difference remained marginally statistically significant after controlling for
247 sociodemographic, health and vaccine-related variables (p=0.045; **Table S2**).

248 The multivariable analyses also revealed that by far the strongest predictors of
249 spike-specific CD4+ and CD8+ T cell responses after three vaccine doses were the
250 corresponding percentage of spike-specific T cells achieved after two doses (**Tables S1,**
251 **S2**). For example, the zero-inflated beta regression estimates for the impact of each 1%
252 increment in post-second dose T cell frequencies on post-third dose frequencies were
253 0.71 for CD4+ T cells (p<2×10⁻¹⁶) and 0.79 for CD8+ T cells (p<2×10⁻¹⁶). To interpret
254 these estimates: if the value of the linear predictor was x for a given set of values of the

255 predictors, and the % of spike-specific CD4+ T cells after two vaccine doses was
256 increased by 1%, the resulting value of the linear predictor would now be $x + 0.71$, which
257 translates to a non-linear increase in the regressed mean from $100 \cdot \logit(x)$ to $100 \cdot \logit(x$
258 $+ 0.71)$, where the factor of 100 converts the proportions to percentages. Male sex,
259 receipt of an mRNA-1273 booster, and, somewhat unexpectedly, a higher number of
260 chronic health conditions, were also independently associated with higher spike-specific
261 CD4+ T cell responses (estimates 0.11 - 0.24; all $p < 0.04$; **Table S1**). We hypothesize that
262 the association between chronic health conditions and better T cell responses is because,
263 after adjusting for post-second-dose responses, individuals with such conditions benefited
264 particularly from a third dose. The association with mRNA-1273 is likely because adults
265 aged 65 years and older, as well as PLWH with a history of immune dysfunction were
266 eligible for the higher (100mcg) mRNA-1273 third dose in British Columbia, whereas the
267 general population received the standard 50 mcg booster dose.

268

269 *Correlations between vaccine-induced T cell responses and other immune measures*

270 The percentages of spike-specific CD4+ and CD8+ T cells were strongly
271 associated with one another after the second vaccine dose (Spearman's $\rho = 0.57$; $p < 0.0001$)
272 as well as after the third dose (Spearman's $\rho = 0.54$; $p < 0.0001$; **Figure 2A**). No association
273 was observed between the percentage of spike-specific CD4+ T cells and the magnitude
274 of vaccine-induced neutralizing antibody responses based on a live-virus assay (reported
275 previously by our group [24]) after either the second (Spearman's $\rho = -0.04$, $p = 0.7$) or third
276 dose (Spearman's $\rho = -0.07$, $p = 0.4$; **Figure 2B**). Prior studies have linked the frequency of

277 CD4+ T follicular helper cells with antibody responses [30], but we did not assess T cell
278 subsets here.

279 As CD4+ T cell counts are used as an indicator of immune function in PLWH, we
280 evaluated the relationship between this parameter and vaccine-induced T cell responses
281 in this group. We observed no association between the most recent CD4+ T cell count
282 and the frequency of either spike-specific CD4+ or CD8+ T cells following the second or
283 third vaccine doses (Spearman's $\rho=-0.09$ to -0.18 ; all $p>0.2$; **Figure S2**). Similarly, we
284 observed no association between nadir CD4+ T cell counts and vaccine-induced CD4+ T
285 cell responses after either dose (Spearman's $\rho=-0.05$ and -0.12 , respectively, both $p>0.4$)
286 (**Figure S2**). By contrast, an unexpected modest negative correlation was found between
287 nadir CD4+ T cell counts and spike-specific CD8+ T cell responses after both the second
288 (Spearman's $\rho=-0.29$, $p=0.04$) and third (Spearman's $\rho=-0.28$, $p=0.05$) dose. We
289 hypothesize that the post-third-dose results are because PLWH with a history of immune
290 dysfunction were eligible for a higher (100 mcg) third dose of mRNA-1273, though this
291 would not explain our post-second-dose results. Regardless, there is no indication that a
292 low nadir CD4+ count impaired T cell responses to COVID-19 vaccination in our cohort.
293

294 ***Breakthrough infection further boosts CD4+ and CD8+ T cell responses***

295 In British Columbia, the initial waves of Omicron BA.1 and BA.2 occurred after
296 the mass administration of third vaccine doses in the province. Of the 50 PLWH studied,
297 21 (42%) PLWH experienced SARS-CoV-2 breakthrough infections between 1 and 6
298 months following their third dose. Post-breakthrough plasma and PBMC specimens were
299 available from nearly all PLWH, so we further examined humoral (neutralizing antibody)

300 and cellular immune responses 6 months after the third dose, and again one month after
301 receipt of a fourth vaccine dose, in the PLWH cohort (n=50) (**Figure 3**). As we reported
302 previously [12, 24], plasma neutralizing antibody activity declined significantly among
303 SARS-CoV-2-naïve individuals after the third vaccine dose, but in those who
304 experienced breakthrough infection, neutralization activity increased to above peak levels
305 induced by vaccination. For example, at 6 months post-third vaccine dose, the median
306 virus neutralization titer (reported as a reciprocal dilution) was 640 (IQR 320-2560) in
307 PLWH who experienced a breakthrough infection, double the observed value in this
308 group after three vaccine doses alone (paired test, $p=0.002$; **Figure 3A**). This
309 neutralization titer was also eight times higher than the median titer of 80 (IQR 20-160)
310 observed at 6 months post-third vaccine dose in PLWH who remained SARS-CoV-2
311 naïve ($p<0.0001$; **Figure 3A**). The observation that neutralization titers increase
312 significantly following breakthrough infection confirms the ongoing presence of spike-
313 specific memory B cells despite diminished neutralizing activity in blood.

314 In contrast to neutralizing antibodies, spike-specific CD4⁺ and CD8⁺ T cell
315 frequencies did not wane in SARS-CoV-2 naïve PLWH following vaccination. In fact,
316 the percentage of both spike-specific CD4⁺ and CD8⁺ T cells increased slightly between
317 1 and 6 months after the third vaccine dose (paired $p=0.003$ and $p=0.005$ respectively,
318 **Figures 3B and 3C**), consistent with the continued presence of vaccine-induced T cells
319 even in the absence of antigen. Like humoral responses however, breakthrough infection
320 boosted T cell responses to levels higher than those observed in the same participants
321 after vaccination alone (both paired tests $p\leq 0.0001$; **Figures 3B and 3C**). Moreover, the
322 median percentage of spike-specific CD4⁺ T cells at 6 months post-third vaccine dose in

323 breakthrough cases was a 1.01% (IQR 0.78-1.51), compared to 0.70% (IQR 0.60-1.02) in
324 SARS-CoV-2- naïve participants at this same time point ($p=0.03$; **Figure 3B**), while the
325 median percentage of spike-specific CD8⁺ T cells in breakthrough cases was 1.20% (IQR
326 0.96-1.55), compared to 0.80% (IQR 0.60-1.02) in SARS-CoV-2 naïve participants at
327 this time point ($p=0.002$; **Figure 3C**).

328 A fourth vaccine dose significantly increased neutralizing antibody responses and
329 spike-specific T cell responses in SARS-CoV-2 naïve PLWH (all paired tests $p\leq 0.0001$;
330 **Figures 3A, 3B, 3C**), illustrating the immune benefit of a fourth vaccine dose in the
331 absence of SARS-CoV-2 infection. A fourth dose also significantly increased humoral
332 and cellular immune responses in PLWH who experienced prior breakthrough infection
333 (all paired tests $p<0.03$; **Figures 3A, 3B, 3C**). Of note, post-fourth dose neutralizing
334 antibody titers and CD8⁺ T cell responses in PLWH who experienced breakthrough
335 infection were significantly higher than among SARS-CoV-2 naïve PLWH at this same
336 time ($p=0.001$ and $p=0.03$ respectively; **Figures 3A and 3C**), consistent with prior
337 reports of superior “hybrid” immunity generated by a combination of vaccination and
338 infection [31, 32].

339

340 *Correlates of protection against breakthrough infection*

341 Given the substantial proportion of participants who experienced their first SARS-
342 CoV-2 breakthrough infection between one and six months following three-dose
343 vaccination (42% of PLWH; 44% of controls), we explored our data for potential
344 correlates of protection. As HIV status was not associated with breakthrough infection
345 ($p=0.86$), PLWH and control groups were combined for analysis, yielding 78 participants

346 who remained SARS-CoV-2 naïve and 59 participants who experienced SARS-CoV-2
347 infection during the follow-up period. Univariable analyses revealed older age to be
348 significantly associated with protection against breakthrough infection: participants
349 remaining SARS-CoV-2 naïve were a median 60 [IQR 42-71] years old while those who
350 experienced breakthrough infection were a median 43 [IQR 34-60] years old (combined
351 cohort $p=0.001$; **Figure 4A**). This observation was largely driven by the control group,
352 which included 29 adults age 70 years or over (compared to 3 in the PLWH group). The
353 percentage of spike-specific CD4⁺ T cells one month after the third vaccine dose was not
354 associated with breakthrough infection ($p=0.72$ for the combined cohort; **Figure 4B**), but
355 a higher percentage of spike-specific CD8⁺ T cells at this time point was associated with
356 remaining SARS-CoV-2 naïve ($p=0.046$ for the combined cohort) (**Figure 4C**). This
357 observation was driven by differences in CD8⁺ T cell responses among PLWH ($p=0.02$)
358 and suggests that cytotoxic T cells specific for SARS-CoV-2 may contribute to
359 protection. Somewhat surprisingly, we found no association between neutralizing
360 antibody responses induced by three vaccine doses and breakthrough infections ($p=0.33$
361 for the combined cohort) (**Figure 4D**), likely because vaccine-induced antibodies against
362 the ancestral (Wuhan) spike had limited activity against the Omicron strains that caused
363 the majority of breakthrough infections, and because these infections occurred a median
364 of 3.7 months after booster vaccination, when circulating antibody titers had declined
365 substantially. In a multivariable logistic regression analysis that incorporated participant
366 sociodemographic, vaccine and immune response variables, older age was the only
367 significant predictor of protection against SARS-CoV-2 breakthrough infection (**Table**
368 **S3**). Though at first surprising, this observation is consistent with the very rapid rise in

369 SARS-CoV-2 anti-N seroprevalence in Canada among younger individuals following the
370 emergence of Omicron, and likely reflects the impact of social/behavioural factors rather
371 than biological factors. For example, by mid-June 2022, anti-N seroprevalence in
372 Canadian adults aged < 25 years was 57%, in those aged 25–39 years it was 51%, in
373 those aged 40–59 years it was 40%, and in those 60 years or older it was 25% [33].
374 Similar age-specific trends were observed in Finland [34] and the USA [35], suggesting
375 that many older adults continued to benefit from efforts to limit exposure to COVID-19
376 in the community, even after the arrival of Omicron.

377

378 **DISCUSSION**

379 We observed that the frequencies of SARS-CoV-2 spike-specific CD4+ and
380 CD8+ T cells were not significantly different between PLWH and controls after two
381 doses of COVID-19 vaccine. Both CD4+ and CD8+ T cell responses were enhanced
382 following a third vaccine dose, but the frequency of spike-specific CD8+ T cells was
383 modestly lower in PLWH compared to controls. PLWH generated robust spike-specific T
384 cell responses following post-vaccine breakthrough infection, reaching levels that were
385 equivalent to those achieved after a fourth vaccine dose in SARS-CoV-2 naïve PLWH.
386 Of note, receiving a fourth vaccine dose after having experienced a breakthrough SARS-
387 CoV-2 infection enhanced immune responses even further, with neutralizing antibody
388 responses and CD8+ T cell responses reaching levels significantly higher than those
389 observed in SARS-CoV-2 naïve individuals after four doses. This finding is consistent
390 with previous reports describing the superiority of “hybrid” immunity generated through
391 a combination of vaccination and infection [31, 32].

392 Our results are broadly consistent with other recent studies showing that vaccine-
393 induced spike-specific T cell responses are equivalent in PLWH and controls without
394 HIV, particularly among PLWH receiving antiretroviral therapy [9, 17-20, 23]. We found
395 no association between CD4⁺ T cell responses and neutralizing antibodies after either
396 two or three vaccine doses, suggesting that sufficient T cell help was provided to
397 stimulate spike-specific B cell responses despite a wide range of antigen-specific CD4⁺ T
398 cell frequencies induced by vaccination. While our results do not rule out potential
399 dysfunction in vaccine-induced T cells among PLWH, our data suggest that the impact of
400 T cell impairment is likely to be modest after the second and third vaccine dose.

401 This study has some limitations. All PLWH were receiving suppressive
402 antiretroviral therapy and had generally preserved CD4⁺ T cell counts, so our
403 observations may not be generalizable to PLWH who have low CD4⁺ T cell counts or
404 untreated HIV. Since this was an observational study, PLWH and control participants
405 were not matched at enrolment. Though we included known variables in multivariable
406 regression analyses, residual effects of variables that differed between groups (e.g. sex,
407 vaccine regimen type) or other unknown factors could influence our results. We also
408 lacked information on the concentration of mRNA-1273 third doses (100 mcg versus 50
409 mcg), and therefore we could not investigate the impact of this on immune responses.
410 While the activation induced marker assay provides a sensitive method to quantify spike-
411 specific CD4⁺ and CD8⁺ T cells, we did not analyze T cell subsets such as follicular
412 helper cells, nor T cell functions such as cytokine production or proliferation, that could
413 reveal differences in the effector activity of vaccine- or infection-induced responses.
414 Finally, since T cell responses were measured using peptide pools spanning only the

415 ancestral spike protein, we cannot comment on the relative dominance of individual T
416 cell epitopes nor on potential changes in the distribution of T cell responses following
417 repeated vaccination or breakthrough infection.

418

419 **CONCLUSIONS**

420 In summary, our study indicates that PLWH who are receiving suppressive
421 antiretroviral therapy mount strong CD4+ and CD8+ T cell responses to COVID-19
422 vaccines that are comparable to those found in individuals without HIV. Repeated
423 exposure to SARS-CoV-2 spike antigen, either through vaccination or infection, further
424 enhanced T cell responses in PLWH. PLWH status was not associated with increased risk
425 of post-vaccine breakthrough infection in our cohort, but older age was found to be a
426 significant predictor of protection against infection, consistent with lower SARS-CoV-2
427 anti-N seropositivity rates among older adults in Canada following the emergence of
428 Omicron [33]. These results further underscore the benefits of COVID-19 vaccination in
429 PLWH.

430

431 **DECLARATIONS**

432 **Ethics approval and consent to participate**

433 Written informed consent was obtained from all participants. This study was
434 approved by the University of British Columbia/Providence Health Care and Simon
435 Fraser University Research Ethics Boards.

436

437 **Consent for publication**

438 Not applicable.

439

440 **Availability of data and materials**

441 The datasets analysed in this study are available from the corresponding author
442 upon reasonable request. Data have also been deposited into the COVID-19 Immunology
443 Task Force (CITF) data bank (<https://portal.citf.mcgill.ca/>).

444

445 **Competing interests**

446 The authors declare that they have no competing interests.

447

448 **Funding**

449 This work was supported by the Public Health Agency of Canada through a
450 COVID-19 Immunology Task Force COVID-19 "Hot Spots" Award (2020-HQ-000120
451 to MGR, ZLB, MAB). Additional funding was received from the Canadian Institutes for
452 Health Research (GA2-177713 to MAB), the Coronavirus Variants Rapid Response
453 Network (FRN-175622 to MAB), the Canada Foundation for Innovation through
454 Exceptional Opportunities Fund – COVID-19 awards (to MAB, MLD, ZLB). FMM was
455 supported by fellowships from the Canadian Institutes of Health Research (CIHR)
456 Canadian HIV Trials Network and Michael Smith Health Research BC (MSHR-BC).
457 FHO was supported by a Ph.D. fellowship from the Sub-Saharan African Network for
458 TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-
459 006). The DELTAS Africa Initiative is an independent funding scheme of the African
460 Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa

461 (AESAs) and supported by the New Partnership for Africa's Development Planning and
462 Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant #
463 107752/Z/15/Z] and the UK government. MCD was supported by a CIHR CGS-M award.
464 MLD and ZLB hold Scholar Awards from MSHR-BC.

465

466 **Authors' contributions**

467 SD, ZLB and MAB led the study. YS and HRL coordinated the study. SD and RK
468 quantified T cell responses by flow cytometry. SD, RK, RW, FM, YS, SS, NM-G, MCD,
469 FHO and EB processed specimens and collected data. PKC performed viral neutralization
470 assays. SD, RK, MAB and ZLB analyzed data. RL performed statistical analyses. MLD
471 and MGR supervised SARS-CoV-2 serum antibody quantification. MH, CTC, MH, MH,
472 MGR and JGSM contributed to cohort establishment. ZLB and MAB drafted the
473 manuscript. All authors contributed to manuscript review and editing.

474

475 **Acknowledgements**

476 We thank the leadership and staff of Providence Health Care, St. Paul's Hospital,
477 the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research and Innovation
478 Centre, and Simon Fraser University for supporting this project. In particular, we thank
479 Landon Young and Bruce Ganase for phlebotomy assistance; Laura Burns for technical
480 assistance; Dr Junine Toy, Dr. Chanson Brumme and Paul Sereda for database assistance;
481 and Drs. Silvia Guillemi, Rolando Barrios, Victor Leung, Janet Simons, Daniel Holmes,
482 Curtis Cooper and Aslam Anis for clinical support and guidance. Finally, we thank the
483 participants, without whom this study would not have been possible.

484 **FIGURE LEGENDS**

485 **Figure 1. SARS-CoV-2 spike-specific T cell responses after COVID-19 vaccination.**

486 *Panel A:* Spike-specific CD4⁺ T cell frequencies before and after two and three-dose
487 COVID-19 vaccination. People living with HIV (PLWH) are in orange; controls without
488 HIV (CTRL) are in blue. All participants are COVID-19 naïve. Red bars indicate median
489 and IQR. The Mann-Whitney U-test was used for between-group comparisons and the
490 Wilcoxon matched pairs test was used for longitudinal paired comparisons. P-values are
491 not corrected for multiple comparisons. *Panel B:* Same as panel A, but for spike-specific
492 CD8⁺ T cell frequencies.

493

494 **Figure 2. Associations between cellular and humoral immune measures after**

495 **COVID-19 vaccination.** *Panel A:* Correlation between spike-specific CD4⁺ and CD8⁺ T
496 cell frequencies one month after the second dose (open circles) and one month after the
497 third dose (closed circles) in people living with HIV (PLWH, in orange) and controls
498 without HIV (in blue). *Panel B:* Correlation between spike-specific CD4⁺ T cell
499 frequencies and SARS-CoV-2 neutralizing antibodies, measured at one month after the
500 second dose (open circles) and one month after the third dose (closed circles) in people
501 living with HIV (PLWH, in orange) and controls without HIV (in blue). All participants
502 are COVID-19 naïve.

503

504 **Figure 3. Longitudinal SARS-CoV-2 spike-specific immune responses in PLWH**

505 **who remained naïve or who experienced their first SARS-CoV-2 infection after**

506 **COVID-19 vaccination.** *Panel A:* SARS-CoV-2 neutralizing antibody titers (reciprocal

507 dilution) in people living with HIV (PLWH) after two, three and four doses of COVID-
508 19 vaccine. Data from the same individual are connected by grey lines. SARS-CoV-2-
509 naïve participants are displayed in orange. SARS-CoV-2 breakthrough participants after
510 the third dose are displayed in green (starting at the point of seroconversion). Note that
511 many antibody titer values overlap, resulting in darker colored symbols. Asterisks denote
512 naive participants who experienced SARS-CoV-2 breakthrough between six months post-
513 dose three and one month post-dose four. Red bars indicate median. The Mann-Whitney
514 U-test was used for between-group comparisons and the Wilcoxon matched pairs test was
515 used for longitudinal paired comparisons. P-values are not corrected for multiple
516 comparisons. *Panel B*: Same as panel A, but for spike-specific CD4⁺ T cell responses.
517 *Panel C*: Same as panels A and B, but for spike-specific CD8⁺ T cell responses. The
518 Mann-Whitney U-test was used for between-group comparisons and the Wilcoxon
519 matched pairs test was used for longitudinal paired comparisons. P-values are not
520 corrected for multiple comparisons.

521

522 **Figure 4. Analysis of correlates of protection against SARS-CoV-2 breakthrough**
523 **infection after COVID-19 vaccination.** *Panel A*: Participant ages are shown at study
524 entry, stratified according to those who remained SARS-CoV-2 naïve (n=78) and those
525 who experienced SARS-CoV-2 breakthrough infection between one and six months after
526 receiving a third vaccine dose (n=59). PLWH are in orange; controls are in blue. *Panel B*:
527 Same as panel A, except the frequencies of spike-specific CD4⁺ T cells one month after
528 three vaccine doses are shown. *Panel C*: Same as panel A and B, except the frequencies
529 of CD8⁺ T cells one month after three vaccine doses are shown. *Panel D*: Same as other

530 panels, except SARS-CoV-2 neutralization activities (reported as reciprocal dilution
531 titers) one month after three vaccine doses are shown. For all panels, the Mann-Whitney
532 U-test was used to compare groups, using data from the full cohort (all; n=137), from
533 controls only (n=87), or from PLWH only (n=50).
534

535 REFERENCES

- 536 1. Boulle A, Davies MA, Hussey H, Ismail M, Morden E, Vundle Z, Zweigenthal V,
537 Mahomed H, Paleker M, Pienaar D *et al*: **Risk factors for COVID-19 death in a**
538 **population cohort study from the Western Cape Province, South Africa.** *Clin Infect*
539 *Dis* 2020.
- 540 2. Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, Villa G,
541 Docherty A, Harrison EM, Turtle L *et al*: **Outcomes of COVID-19 related**
542 **hospitalization among people with HIV in the ISARIC WHO Clinical**
543 **Characterization Protocol (UK): a prospective observational study.** *Clin Infect Dis*
544 2020.
- 545 3. Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, Eggo
546 RM, Morton CE, Bacon SCJ, Inglesby P *et al*: **HIV infection and COVID-19 death: a**
547 **population-based cohort analysis of UK primary care data and linked national**
548 **death registrations within the OpenSAFELY platform.** *Lancet HIV* 2021, 8(1):e24-
549 e32.
- 550 4. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, Gonzalez
551 CJ, Udo T, Morne JE, Hart-Malloy R *et al*: **COVID-19 Outcomes Among Persons**
552 **Living With or Without Diagnosed HIV Infection in New York State.** *JAMA network*
553 *open* 2021, 4(2):e2037069.
- 554 5. Spinelli MA, Jones BLH, Gandhi M: **COVID-19 Outcomes and Risk Factors**
555 **Among People Living with HIV.** *Curr HIV/AIDS Rep* 2022, 19(5):425-432.
- 556 6. Chambers C, Samji H, Cooper CL, Costiniuk CT, Janjua NZ, Kroch AE, Arbess
557 G, Benoit AC, Buchan SA, Chung H *et al*: **Coronavirus disease 2019 vaccine**
558 **effectiveness among a population-based cohort of people living with HIV.** *AIDS*
559 2022, 36(15):F17-F26.
- 560 7. Fowokan A, Samji H, Puyat JH, Janjua NZ, Wilton J, Wong J, Grennan T,
561 Chambers C, Kroch A, Costiniuk CT *et al*: **Effectiveness of COVID-19 vaccines in**
562 **people living with HIV in British Columbia and comparisons with a matched HIV-**
563 **negative cohort: a test-negative design.** *Int J Infect Dis* 2023, 127:162-170.
- 564 8. Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD,
565 Dheda K, Barnabas SL, Bhorat QE *et al*: **Safety and immunogenicity of the ChAdOx1**
566 **nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without**
567 **HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-**
568 **controlled, phase 1B/2A trial.** *Lancet HIV* 2021, 8(9):e568-e580.
- 569 9. Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S,
570 De Pascale L, Matusali G, Mariotti D *et al*: **Humoral and Cellular Immune Response**
571 **Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome**
572 **Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency**

- 573 **Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte**
574 **Count.** *Clin Infect Dis* 2022, **75**(1):e552-e563.
- 575 10. Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC,
576 Yaseen F, Agafitei O, Ennis S, Ng K *et al*: **Humoral immune responses to COVID-19**
577 **vaccination in people living with HIV receiving suppressive antiretroviral therapy.**
578 *NPJ Vaccines* 2022, **7**(1):28.
- 579 11. Jedicke N, Stankov MV, Cossmann A, Dopfer-Jablonka A, Knuth C, Ahrenstorf
580 G, Ramos GM, Behrens GMN: **Humoral immune response following prime and boost**
581 **BNT162b2 vaccination in people living with HIV on antiretroviral therapy.** *HIV Med*
582 2022, **23**(5):558-563.
- 583 12. Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad
584 E, Moran-Garcia N, Datwani S, Duncan MC *et al*: **Antibody response durability**
585 **following three-dose COVID-19 vaccination in people with HIV receiving**
586 **suppressive ART.** *AIDS* 2022.
- 587 13. Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G,
588 Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S *et al*: **People with HIV**
589 **receiving suppressive antiretroviral therapy show typical antibody durability after**
590 **dual COVID-19 vaccination, and strong third dose responses.** *J Infect Dis* 2022.
- 591 14. Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrrière
592 V, Trottier B, Richard J, Durand M, Kaufmann D *et al*: **Covid-19 vaccine**
593 **immunogenicity in people living with HIV-1.** *Vaccine* 2022, **40**(26):3633-3637.
- 594 15. Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, Meschi S,
595 Iannazzo R, Mazzotta V, Colavita F *et al*: **Immunogenicity to COVID-19 mRNA**
596 **vaccine third dose in people living with HIV.** *Nat Commun* 2022, **13**(1):4922.
- 597 16. Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O,
598 Cox AL, Blankson JN: **The BNT162b2 mRNA Vaccine Elicits Robust Humoral and**
599 **Cellular Immune Responses in People Living With Human Immunodeficiency Virus**
600 **(HIV).** *Clin Infect Dis* 2022, **74**(7):1268-1270.
- 601 17. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, Alagaratnam J, Aley PK,
602 Ali M, Ansari MA *et al*: **Safety and immunogenicity of the ChAdOx1 nCoV-19**
603 **(AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of**
604 **a phase 2/3 clinical trial.** *Lancet HIV* 2021, **8**(8):e474-e485.
- 605 18. Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, Adele S,
606 Alagaratnam J, Ali M, Aley PK *et al*: **Booster vaccination against SARS-CoV-2**
607 **induces potent immune responses in people with HIV.** *Clin Infect Dis* 2022.
- 608 19. Hensley KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, Mueller YM, Dalm V,
609 Papageorgiou G, Steggink H, Gorska A, Bogers S *et al*: **Immunogenicity and**
610 **reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the**

- 611 **Netherlands: A nationwide prospective cohort study.** *PLoS Med* 2022,
612 **19(10):e1003979.**
- 613 20. Hung CY, Hsiao SH, Huang CG, Chang CS, Chen GY, Huang YL, Dutta A,
614 Huang CT: **Relatively preserved functional immune capacity with standard COVID-**
615 **19 vaccine regimen in people living with HIV.** *Front Immunol* 2023, **14**:1204314.
- 616 21. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A,
617 Pascal K, Quandt J, Maurus D *et al*: **COVID-19 vaccine BNT162b1 elicits human**
618 **antibody and T(H)1 T cell responses.** *Nature* 2020, **586(7830):594-599.**
- 619 22. Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter
620 AE, Herati RS, Oldridge DA, Gouma S *et al*: **Rapid induction of antigen-specific**
621 **CD4(+) T cells is associated with coordinated humoral and cellular immunity to**
622 **SARS-CoV-2 mRNA vaccination.** *Immunity* 2021, **54(9):2133-2142 e2133.**
- 623 23. Matsumoto Y, Murata M, Ohta A, Yamasaki S, Ikezaki H, Toyoda K, Shimono
624 N: **The humoral and cellular immune responses following booster vaccination with**
625 **SARS-CoV-2 mRNA in people living with human immunodeficiency virus.** *J Infect*
626 *Chemother* 2023.
- 627 24. Cheung PK, Lapointe HR, Sang Y, Ennis S, Mwimanzi F, Speckmaier S, Barad
628 E, Dong W, Liang R, Simons J *et al*: **SARS-CoV-2 live virus neutralization after four**
629 **COVID-19 vaccine doses in PWH receiving ART.** *AIDS* 2023, **Accepted, In Press.**
- 630 25. PHAoC: **NACI rapid response: Extended dose intervals for COVID-19**
631 **vaccines to optimize early vaccine rollout and population protection in Canada.**
632 [https://www.canada.ca/en/public-health/services/immunization/national-advisory-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)
633 [committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html)
634 [vaccines-early-rollout-population-protection.html](https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html); 2021.
- 635 26. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M,
636 Talbot D, Prystajek N, Tyson JR, Gilca R *et al*: **Two-Dose Severe Acute Respiratory**
637 **Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and**
638 **Extended Dosing Intervals: Test-Negative Design Studies From British Columbia**
639 **and Quebec, Canada.** *Clin Infect Dis* 2022, **75(11):1980-1992.**
- 640 27. Buchan SA, Seo CY, Johnson C, Alley S, Kwong JC, Nasreen S, Calzavara A, Lu
641 D, Harris TM, Yu K *et al*: **Epidemiology of Myocarditis and Pericarditis Following**
642 **mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among**
643 **Adolescents and Adults in Ontario, Canada.** *JAMA Netw Open* 2022, **5(6):e2218505.**
- 644 28. Organization WH: **Interim recommendations for use of the Moderna mRNA-**
645 **1273 vaccine against COVID-19.** In.; 2021.
- 646 29. **Weekly update on Variants of Concern** [[http://www.bccdc.ca/health-](http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data)
647 [info/diseases-conditions/covid-19/data](http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data)]

- 648 30. Lv Z, Lv S, Li Q, Xia Y, Feng Z, Zhang H, Yang H, Wu Z, Zou N, Mo Q *et al*: **A**
649 **third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity**
650 **and T follicular helper cell responses in people living with HIV**. *Front Immunol* 2023,
651 **14**:1264160.
- 652 31. Bertoletti A, Le Bert N, Tan AT: **SARS-CoV-2-specific T cells in the changing**
653 **landscape of the COVID-19 pandemic**. *Immunity* 2022, **55**(10):1764-1778.
- 654 32. Lapuente D, Winkler TH, Tenbusch M: **B-cell and antibody responses to**
655 **SARS-CoV-2: infection, vaccination, and hybrid immunity**. *Cell Mol Immunol* 2024,
656 **21**(2):144-158.
- 657 33. Murphy TJ, Swail H, Jain J, Anderson M, Awadalla P, Behl L, Brown PE,
658 Charlton CL, Colwill K, Drews SJ *et al*: **The evolution of SARS-CoV-2 seroprevalence**
659 **in Canada: a time-series study, 2020-2023**. *CMAJ* 2023, **195**(31):E1030-E1037.
- 660 34. Ahava MJ, Jarva H, Jaaskelainen AJ, Lappalainen M, Vapalahti O, Kurkela S:
661 **Rapid increase in SARS-CoV-2 seroprevalence during the emergence of Omicron**
662 **variant, Finland**. *Eur J Clin Microbiol Infect Dis* 2022.
- 663 35. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, Gundlapalli AV, Hall
664 AJ, MacNeil A: **Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies -**
665 **United States, September 2021-February 2022**. *MMWR Morb Mortal Wkly Rep* 2022,
666 **71**(17):606-608.
667

Table 1: Participant characteristics

Characteristic	PLWH (n=50)	Controls (n=87)
Sociodemographic and health variables^a		
Age in years, median [IQR]	58 [42-65]	50 [35-72]
Female sex at birth, n (%)	6 (12%)	58 (67%)
Non-white ethnicity, n (%)	14 (28%)	37 (43%)
Number of chronic health conditions, median [IQR] ^b	1 [0-1]	0 [0-1]
HIV plasma viral load (RNA copies per mL)	<50 [<50-<50]	N.A.
Recent CD4 cell count (per mm ³), median [IQR]	695 [468-983]	N.A.
Nadir CD4 cell count (per mm ³), median [IQR]	250 [140-490]	N.A.
Vaccine details		
Initial regimen ^c		
mRNA only, n (%)	42 (84%)	84 (97%)
ChAdOx1-containing, n (%)	8 (16%)	3 (3%)
Third dose		
BNT162b2, n (%)	17 (34%)	34 (39%)
mRNA-1273, n (%)	33 (66%)	53 (61%)
Days between first and second doses, median [IQR]	59 [53-68]	89 [73-98]
Days between second and third doses, median [IQR]	182 [141-191]	197 [169-215]
Post-3rd vaccine dose SARS-CoV-2 infections, n (%)^d	21 (42%)	38 (44%)

^aSociodemographic, health, and vaccine data were collected by self-report and confirmed through medical records where available. CD4+ T cell counts and HIV plasma viral loads were obtained from medical records.

^bChronic conditions were defined as hypertension, diabetes, asthma, obesity, chronic diseases of lung, liver, kidney, heart or blood, cancer, and immunosuppression due to chronic conditions or medication.

^cInitial regimen refers to the first two doses. "mRNA only" refers to participants who received BNT162b2 and/or mRNA-1273 while "ChAdOx1-containing" refers to participants who received two ChAdOx1 doses, or one ChAdOx1 dose plus one mRNA dose.

^dSARS-CoV-2 infections that occurred between one and six months after the third vaccine dose.

Figure 1






Figure 2

A



B




Figure 3




Figure 4




TABLE S1. Multivariable zero-inflated beta regressions exploring the relationship between sociodemographic, health and vaccine-related variables on Spike-specific CD4+ T cell responses following two and three COVID-19 vaccine doses

Variable	Outcome measures					
	% Spike-responsive CD4+ T cells after two vaccine doses			% Spike-responsive CD4+ T cells after three vaccine doses		
	Estimate	Standard error	P value	Estimate	Standard error	P value
PLWH group	-0.29	0.17	0.08	-0.06	0.10	0.58
Age (per year)	0.001	0.004	0.83	-0.004	0.002	0.08
Male sex	0.13	0.14	0.38	0.24	0.084	0.0044
White ethnicity	-0.19	0.14	0.16	-0.045	0.076	0.55
Health conditions (per condition) ^a	-0.03	0.08	0.72	0.11	0.047	0.022
ChAdOx1-containing initial vaccine regimen ^b	0.37	0.21	0.09	0.14	0.12	0.27
Days between 1st and 2nd vaccine dose (per day)	0.005	0.003	0.12	0.002	0.002	0.30
mRNA-1273 as third vaccine dose ^c	N.A.	N.A.	N.A.	0.17	0.077	0.033
Days between 2nd and 3rd vaccine dose (per day)	N.A.	N.A.	N.A.	0.001	0.001	0.47
% Spike specific T cells after two doses (per 1% increment)	N.A.	N.A.	N.A.	0.71	0.058	<2x10⁻¹⁶

^aContinuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥ 30), chronic diseases of lung, liver, kidney or heart

^bBinary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)

TABLE S2. Multivariable zero-inflated beta regressions exploring the relationship between sociodemographic, health and vaccine-related variables on Spike-specific CD8+ T cell responses following two and three COVID-19 vaccine doses

Variable	Outcome measures					
	% Spike-responsive CD8+ T cells after two vaccine doses			% Spike-responsive CD8+ T cells after three vaccine doses		
	Estimate	Standard error	P value	Estimate	Standard error	P value
PLWH group	-0.0002	0.16	0.99	-0.24	0.12	0.045
Age (per year)	-0.001	0.004	0.87	0.001	0.004	0.87
Male sex	0.18	0.14	0.20	0.11	0.10	0.24
White ethnicity	0.14	0.13	0.30	-0.01	0.08	0.90
Health conditions (per condition) ^a	-0.02	0.08	0.75	-0.05	0.06	0.37
ChAdOx1-containing initial vaccine regimen ^b	0.39	0.20	0.049	0.22	0.14	0.12
Days between 1st and 2nd vaccine dose (per day)	0.002	0.003	0.54	0.00	0.00	0.16
mRNA-1273 as third vaccine dose ^c	N.A.	N.A.	N.A.	0.02	0.11	0.86
Days between 2nd and 3rd vaccine dose (per day)	N.A.	N.A.	N.A.	-0.001	0.002	0.43
% Spike specific T cells after two doses (per 1% increment)	N.A.	N.A.	N.A.	0.79	0.07	<2e-16

^aContinuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥ 30), chronic diseases of lung, liver, kidney or heart

^bBinary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)

TABLE S3. Multivariable logistic regression looking at factors associated with risk of first breakthrough infection between 1 and 6 months following receipt of the 3rd COVID-19 vaccine dose

Variables	Estimate	95% CI	P value
PLWH group	0.93	0.30 to 2.78	0.89
Age (per year)	0.96	0.93 to 0.98	0.002
Male sex	0.68	0.27 to 1.66	0.40
White ethnicity	1.55	0.69 to 3.60	0.29
Health conditions (per condition) ^a	1.22	0.72 to 2.09	0.46
ChAdOx1-containing initial vaccine regimen ^b	2.02	0.52 to 8.27	0.31
Days between 1st and 2nd vaccine dose (per day)	1.00	0.97 to 1.02	0.76
mRNA-1273 as third vaccine dose ^c	1.09	0.49 to 2.47	0.84
Days between 2nd and 3rd vaccine dose (per day)	1.00	0.99 to 1.01	0.96
% Spike specific CD4+ T cells after three doses (per 1% increment)	0.76	0.25 to 2.13	0.61
% Spike specific CD8+ T cells after two doses (per 1% increment)	0.86	0.36 to 2.01	0.73
Virus neutralizing activity (per 1% increment)	1.00	0.99 to 1.00	0.26

^aContinuous variable, defined as: chronic blood disorder, cancer, hypertension, diabetes, asthma, obesity (body mass index ≥ 30), chronic diseases of lung, liver, kidney or heart

^bBinary variable, defined as two doses of ChAdOx1, or a heterologous regimen consisting of one dose each of ChAdOx1 and an mRNA vaccine (mRNA-1273 or BNT162b2) (vs. a reference group defined as two doses of mRNA vaccine)

^cBinary variable, defined as a third dose of mRNA-1273 (vs. a reference group defined as a third dose of BNT162b2)




Figure S1. Gating strategy used to quantify vaccine-induced spike-specific T cell responses by flow cytometry.







Figure S2. Correlations between vaccine-induced spike-specific T cell responses and recent or nadir CD4 cell count in PLWH.